Growth and disease burden in children with hypophosphatasia.

body mass index growth height hypophosphatasia registry

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 16 02 2023
accepted: 14 03 2023
medline: 15 3 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: epublish

Résumé

Hypophosphatasia, an inborn error of metabolism characterized by impaired bone mineralization, can affect growth. This study evaluated relationships between anthropometric parameters (height, weight, and body mass index) and clinical manifestations of hypophosphatasia in children. Data from children (aged <18 years) with hypophosphatasia were analyzed from the observational Global Hypophosphatasia Registry. Anthropometric parameters were evaluated by age group (<2 years and ≥2 years) at assessment. The frequency of hypophosphatasia manifestations was compared between children with short stature (< percentile) and those with normal stature. This analysis included 215 children (54.4% girls). Short stature presented in 16.1% of children aged <2 years and 20.4% of those aged ≥2 years at assessment. Among those with available data (n = 62), height was below the target height (mean: -0.66 standard deviations). Substantial worsening of growth (mean delta height z score: -1.45; delta weight z score: -0.68) occurred before 2 years of age, while in those aged ≥2 years, anthropometric trajectories were maintained (delta height z score: 0.08; delta weight z score: 0.13). Broad-ranging hypophosphatasia manifestations (beyond dental) were observed in most children. Short stature was not a consistent characteristic of children with hypophosphatasia, but growth impairment was observed in those aged <2 years, indicating that hypophosphatasia might affect growth plate activity during infancy. In addition, a broad range of clinical manifestations occurred in those above and below the third percentile for height, suggesting that height alone may not accurately reflect hypophosphatasia disease burden and that weight is less affected than longitudinal growth.

Identifiants

pubmed: 36917043
doi: 10.1530/EC-22-0240
pii: EC-22-0240
pmc: PMC10160547
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

Rheumatol Int. 2011 Oct;31(10):1315-20
pubmed: 20383509
Metabolism. 2016 Oct;65(10):1522-30
pubmed: 27621187
Orphanet J Rare Dis. 2019 Aug 16;14(1):201
pubmed: 31419999
Bone. 2021 Jan;142:115664
pubmed: 32987199
Arch Dis Child. 1970 Dec;45(244):819
pubmed: 21032457
BMC Musculoskelet Disord. 2019 Feb 14;20(1):80
pubmed: 30764793
Nat Rev Endocrinol. 2016 Apr;12(4):233-46
pubmed: 26893260
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8
pubmed: 23858621
Childs Nerv Syst. 2009 Feb;25(2):217-23
pubmed: 18769927
Clin Biochem Rev. 2020 Feb;41(1):13-27
pubmed: 32158059
Orphanet J Rare Dis. 2022 Jul 19;17(1):277
pubmed: 35854311
Bone. 2016 Dec;93:125-138
pubmed: 27576207
Vaccine. 2017 Dec 4;35(48 Pt A):6492-6500
pubmed: 29150054

Auteurs

Wolfgang Högler (W)

Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Agnès Linglart (A)

AP-HP, Hôpital Bicêtre Paris Saclay, service d'endocrinologie et diabète de l'enfant, DMU 3 SEA, centre de référence des maladies rares du métabolisme du calcium et du phosphate, filière OSCAR; Université de Paris-Saclay INSERM U1185, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Anna Petryk (A)

Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.

Priya S Kishnani (PS)

Duke University Medical Center, Durham, North Carolina, USA.

Lothar Seefried (L)

University of Würzburg, Würzburg, Germany.

Shona Fang (S)

Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.

Cheryl Rockman-Greenberg (C)

University of Manitoba, Winnipeg, Manitoba, Canada.

Keiichi Ozono (K)

Osaka University, Suita, Osaka, Japan.

Kathryn Dahir (K)

Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Gabriel Ángel Martos-Moreno (GÁ)

Departments of Pediatrics and Pediatric Endocrinology Hospital Infantil Universitario Niño Jesús, IIS La Princesa, Universidad Autónoma de Madrid, CIBERobn, ISCIII, Madrid, Spain.

Classifications MeSH